<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Cell</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Cell</journal-id><journal-title-group><journal-title>Cancer Cell</journal-title></journal-title-group><issn pub-type="ppub">1535-6108</issn><issn pub-type="epub">1878-3686</issn><publisher><publisher-name>Cell Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25314077</article-id><article-id pub-id-type="pmc">4197335</article-id><article-id pub-id-type="publisher-id">S1535-6108(14)00315-8</article-id><article-id pub-id-type="doi">10.1016/j.ccr.2014.07.027</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Cancer-Selective Targeting of the NF-&#x003ba;B Survival Pathway with GADD45&#x003b2;/MKK7 Inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tornatore</surname><given-names>Laura</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Sandomenico</surname><given-names>Annamaria</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Raimondo</surname><given-names>Domenico</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Low</surname><given-names>Caroline</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Rocci</surname><given-names>Alberto</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Tralau-Stewart</surname><given-names>Cathy</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Capece</surname><given-names>Daria</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Andrea</surname><given-names>Daniel</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Bua</surname><given-names>Marco</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Boyle</surname><given-names>Eileen</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>van&#x000a0;Duin</surname><given-names>Mark</given-names></name><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Zoppoli</surname><given-names>Pietro</given-names></name><xref rid="aff9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>Jaxa-Chamiec</surname><given-names>Albert</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Thotakura</surname><given-names>Anil&#x000a0;K.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Dyson</surname><given-names>Julian</given-names></name><xref rid="aff10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name><surname>Walker</surname><given-names>Brian&#x000a0;A.</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Leonardi</surname><given-names>Antonio</given-names></name><xref rid="aff11" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name><surname>Chambery</surname><given-names>Angela</given-names></name><xref rid="aff12" ref-type="aff">12</xref><xref rid="aff13" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name><surname>Driessen</surname><given-names>Christoph</given-names></name><xref rid="aff14" ref-type="aff">14</xref></contrib><contrib contrib-type="author"><name><surname>Sonneveld</surname><given-names>Pieter</given-names></name><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Morgan</surname><given-names>Gareth</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Palumbo</surname><given-names>Antonio</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Tramontano</surname><given-names>Anna</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff15" ref-type="aff">15</xref></contrib><contrib contrib-type="author"><name><surname>Rahemtulla</surname><given-names>Amin</given-names></name><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Ruvo</surname><given-names>Menotti</given-names></name><email>menotti.ruvo@unina.it</email><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author"><name><surname>Franzoso</surname><given-names>Guido</given-names></name><email>g.franzoso@imperial.ac.uk</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medicine, Centre for Cell Signalling and Inflammation, Imperial College London, London W12 0NN, UK</aff><aff id="aff2"><label>2</label>Institute of Biostructures and Bioimages, National Research Council and CIRPeB, 80134 Naples, Italy</aff><aff id="aff3"><label>3</label>Department of Physics, &#x0201c;Sapienza&#x0201d; University, 00185 Rome, Italy</aff><aff id="aff4"><label>4</label>Drug Discovery Centre, Imperial College London, London W6 8RP, UK</aff><aff id="aff5"><label>5</label>Division of Hematology, University of Torino, AOU San Giovanni Battista, 10126 Turin, Italy</aff><aff id="aff6"><label>6</label>Department of Medicine, Centre for Haematology, Imperial College London, London W12 0NN, UK</aff><aff id="aff7"><label>7</label>Section of Haemato-Oncology, The Institute of Cancer Research, London SM2 5NG, UK</aff><aff id="aff8"><label>8</label>Department of Hematology, Erasmus University Medical Center, 3000 CA Rotterdam, the Netherlands</aff><aff id="aff9"><label>9</label>Institute for Cancer Genetics, Columbia University Medical Center, New York, NY 10032, USA</aff><aff id="aff10"><label>10</label>Department of Medicine, Section of Molecular Immunology, Imperial College London, London W12 0NN, UK</aff><aff id="aff11"><label>11</label>Department of Molecular Medicine and Medical Biotechnologies, University of Naples &#x0201c;Federico II,&#x0201d; 80131 Naples, Italy</aff><aff id="aff12"><label>12</label>Department of Environmental, Biological, and Pharmaceutical Sciences and Technologies, Second University of Naples, 81100 Caserta, Italy</aff><aff id="aff13"><label>13</label>IRCCS Multimedica, 20138 Milan, Italy</aff><aff id="aff14"><label>14</label>Department of Oncology/Hematology, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland</aff><aff id="aff15"><label>15</label>Istituto Pasteur Fondazione Cenci Bolognetti, &#x0201c;Sapienza&#x0201d; University, 00185 Rome, Italy</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author <email>menotti.ruvo@unina.it</email></corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Corresponding author <email>g.franzoso@imperial.ac.uk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>13</day><month>10</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.--><pub-date pub-type="ppub"><day>13</day><month>10</month><year>2014</year></pub-date><volume>26</volume><issue>4</issue><fpage>495</fpage><lpage>508</lpage><history><date date-type="received"><day>21</day><month>2</month><year>2014</year></date><date date-type="rev-recd"><day>26</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>29</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 The Authors. Published by Elsevier Inc.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Elsevier Inc.</copyright-holder></permissions><abstract><title>Summary</title><p>Constitutive NF-&#x003ba;B signaling promotes survival in multiple myeloma (MM) and other cancers; however, current NF-&#x003ba;B-targeting strategies lack cancer cell specificity. Here, we identify the interaction between the NF-&#x003ba;B-regulated antiapoptotic factor GADD45&#x003b2; and the JNK kinase MKK7 as a therapeutic target in MM. Using a drug-discovery strategy, we developed DTP3, a D-tripeptide, which disrupts the GADD45&#x003b2;/MKK7 complex, kills MM cells effectively, and, importantly, lacks toxicity to normal cells. DTP3 has similar anticancer potency to the clinical standard, bortezomib, but more than 100-fold higher cancer cell specificity in&#x000a0;vitro. Notably, DTP3 ablates myeloma xenografts in mice with no apparent side effects at the effective doses. Hence, cancer-selective targeting of the NF-&#x003ba;B pathway is possible and, at least for myeloma patients, promises a profound benefit.</p></abstract><abstract abstract-type="author-highlights"><title>Highlights</title><p><list list-type="simple"><list-item id="u0010"><label>&#x02022;</label><p>GADD45&#x003b2; is a critical mediator of the NF-&#x003ba;B antiapoptotic function in MM</p></list-item><list-item id="u0015"><label>&#x02022;</label><p>GADD45&#x003b2; binds to MKK7 and promotes MM cell survival by blocking MKK7/JNK signaling</p></list-item><list-item id="u0020"><label>&#x02022;</label><p>GADD45&#x003b2;/MKK7 inhibitors display potent activity against MM, in&#x000a0;vitro and in&#x000a0;vivo</p></list-item><list-item id="u0025"><label>&#x02022;</label><p>GADD45&#x003b2;/MKK7 inhibitors are far more cancer selective than IKK/NF-&#x003ba;B inhibitors</p></list-item></list></p></abstract><abstract abstract-type="teaser"><p>NF-&#x003ba;B is implicated in MM and other malignancies, but it is challenging to block NF-&#x003ba;B only in diseased cells. Tornatore et&#x000a0;al. identify an interaction between MKK7 and NF-&#x003ba;B-regulated GADD45&#x003b2; as a therapeutic target and develop a peptide that disrupts the complex and selectively kills MM cells.</p></abstract></article-meta></front><body><sec id="sec1"><title>Significance</title><p><bold>NF-&#x003ba;B has been implicated in many inflammatory and malignant diseases, such as MM. Yet therapeutically targeting this pathway has proved an insurmountable challenge. The conundrum with current strategies has been how to block NF-&#x003ba;B in a disease-specific manner, given NF-&#x003ba;B&#x02019;s pleiotropic and ubiquitous functions. Here, we have achieved this goal in the context of MM. Rather than targeting NF-&#x003ba;B, we targeted the downstream module, GADD45&#x003b2;/MKK7, within a pathogenically critical and cancer-restricted axis of the NF-&#x003ba;B pathway. We demonstrate that agents targeting this axis are both highly effective against MM and well tolerated in&#x000a0;vivo, with far greater cancer cell specificity than global NF-&#x003ba;B inhibitors. Plausibly, the same principle could be applied for targeting NF-&#x003ba;B disease selectively also in pathologies beyond MM.</bold></p></sec><sec sec-type="intro" id="sec2"><title>Introduction</title><p>In addition to orchestrating immune and inflammatory responses, NF-&#x003ba;B transcription factors play a crucial role in oncogenesis (<xref rid="bib37" ref-type="bibr">Staudt, 2010</xref>). NF-&#x003ba;B is aberrantly activated in a wide range of human cancers, in which it promotes survival and malignancy by upregulating antiapoptotic genes (<xref rid="bib37 bib13" ref-type="bibr">Staudt, 2010; DiDonato et&#x000a0;al., 2012</xref>). The paradigm of these cancers is multiple myeloma (MM), an incurable malignancy of plasma cells (PCs), accounting for nearly 2% of all cancer deaths (<xref rid="bib18" ref-type="bibr">Kuehl and Bergsagel, 2002</xref>). The current treatment for MM includes chemotherapy and steroids combined with newer agents, such as proteasome inhibitors and immunomodulatory drugs (IMiDs), whereas stem cell transplantation is an option for select patients. These treatments, however, generally achieve only temporary remissions, and so most patients eventually relapse and/or develop drug resistance (<xref rid="bib33 bib22" ref-type="bibr">Rajkumar, 2011; Mahindra et&#x000a0;al., 2012</xref>). Thus, despite the introduction of new treatments, the management of myeloma patients remains a major medical problem. Consequently, there is a need for more effective therapeutic approaches targeting defined oncogenetic events in&#x000a0;MM.</p><p>Compelling evidence has established the paramount importance of aberrant NF-&#x003ba;B signaling in MM pathogenesis (<xref rid="bib37 bib13" ref-type="bibr">Staudt, 2010; DiDonato et&#x000a0;al., 2012</xref>). The most conclusive affirmation of this key role of NF-&#x003ba;B in MM has come from the discovery of a diverse array of genetic alterations targeting components of the NF-&#x003ba;B pathway, such as the upstream activator, NF-&#x003ba;B-inducing kinase and the inhibitor tumor necrosis factor receptor-associated factor 3, in about 20% of MM patients and more than 40% of MM cell lines (<xref rid="bib1 bib17 bib10 bib5" ref-type="bibr">Annunziata et&#x000a0;al., 2007; Keats et&#x000a0;al., 2007; Demchenko et&#x000a0;al., 2010; Chapman et&#x000a0;al., 2011</xref>). Irrespective of their nature, these oncogenic lesions lead to constitutive activation of both main pathways of NF-&#x003ba;B signaling, namely, the classical and alternative pathways (<xref rid="bib17 bib1 bib37 bib13" ref-type="bibr">Keats et&#x000a0;al., 2007; Annunziata et&#x000a0;al., 2007; Staudt, 2010; DiDonato et&#x000a0;al., 2012</xref>). In fact, even in those patients with no recognizable NF-&#x003ba;B-pathway mutations, MM cells constitutively engage these pathways via stimuli emanating from the tumor microenvironment (<xref rid="bib15 bib37" ref-type="bibr">Hideshima et&#x000a0;al., 2005; Staudt, 2010</xref>). Consequently, more than 80% of all primary MM cells and the vast majority of&#x000a0;MM cell lines display nuclear accumulation of NF-&#x003ba;B and high NF-&#x003ba;B target gene signature, leading to NF-&#x003ba;B-pathway addiction and sensitivity to apoptosis upon I&#x003ba;B&#x003b1; kinase (IKK) &#x003b2;/NF-&#x003ba;B inhibition (<xref rid="bib37" ref-type="bibr">Staudt, 2010</xref>).</p><p>Collectively, these findings provide a strong rationale for therapeutically targeting the NF-&#x003ba;B pathway in MM. However, despite the pharmaceutical industry&#x02019;s aggressive effort to develop specific NF-&#x003ba;B or IKK&#x003b2; inhibitors for indication both within and outside of oncology, no such inhibitor has been clinically approved, because of the preclusive toxicities associated with the global suppression of NF-&#x003ba;B (<xref rid="bib13" ref-type="bibr">DiDonato et&#x000a0;al., 2012</xref>). Similarly, proteasome inhibitors with clinical indication in MM, such as bortezomib, inhibit many essential cellular pathways that rely on proteasome function, among which is the NF-&#x003ba;B pathway, and, furthermore, target these pathways in normal and cancer cells alike, thus resulting in a low therapeutic index and dose-limiting toxicities (<xref rid="bib34 bib6" ref-type="bibr">Richardson, 2010; Chen et&#x000a0;al., 2011</xref>). Indeed, it is unclear that the clinical activity of proteasome inhibitors in MM, as well as that of IMiDs, which too have broad molecular specificity and can affect NF-&#x003ba;B signaling, is due to the inhibition of NF-&#x003ba;B (<xref rid="bib37 bib6 bib24" ref-type="bibr">Staudt, 2010; Chen et&#x000a0;al., 2011; McCurdy and Lacy, 2013</xref>).</p><p>The conundrum with conventional NF-&#x003ba;B-targeting strategies has been how to achieve cancer cell specificity, given the ubiquitous nature and pleiotropic physiological functions of NF-&#x003ba;B (<xref rid="bib13" ref-type="bibr">DiDonato et&#x000a0;al., 2012</xref>). Because a key pathogenetic activity of NF-&#x003ba;B in MM is to block apoptosis through the induction of target genes, an attractive alternative to globally targeting NF-&#x003ba;B would be to block the nonredundant, cancer-specific downstream effectors of the NF-&#x003ba;B survival function; these effectors, however, are not known. To develop a strategy for inhibiting the NF-&#x003ba;B pathway in a cancer-selective manner and, thus, exploiting its therapeutic potential, we therefore sought to delineate the mechanism(s) underlying the pathological survival activity of constitutive NF-&#x003ba;B signaling in MM. Further, we sought to develop a pharmacological inhibitor of this mechanism(s) in order to kill MM cells effectively and without toxicity to normal cells.</p></sec><sec sec-type="results" id="sec3"><title>Results</title><sec id="sec3.1"><title><italic>GADD45B</italic> Expression Denotes More Aggressive Disease in MM</title><p>Given their key role in oncogenesis, we sought to investigate the&#x000a0;downstream mechanisms mediating NF-&#x003ba;B survival signaling in MM. Because this signaling involves the induction of antiapoptotic NF-&#x003ba;B target genes, and we had previously identified the <italic>GADD45</italic>-family gene, <italic>GADD45B</italic>, as a transcriptional target of NF-&#x003ba;B encoding a potent and selective inhibitor of the JNK MAPK pathway and, therefore, of apoptosis (<xref rid="bib11 bib28" ref-type="bibr">De Smaele et&#x000a0;al., 2001; Papa et&#x000a0;al., 2004</xref>), we investigated the involvement of this gene in MM. <italic>GADD45B</italic> was markedly upregulated in monoclonal CD138<sup>+</sup> PCs from MM patients compared with monoclonal PCs from patients with monoclonal gammopathy of undetermined significance (MGUS), a premalignant condition (<xref rid="bib19" ref-type="bibr">Kyle and Rajkumar, 2009</xref>), or healthy polyclonal PCs (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A), thus establishing a correlation between <italic>GADD45B</italic> mRNA expression and PC malignancy. Strikingly, when MM patients were stratified at diagnosis on the basis of the <italic>GADD45B</italic> mRNA expression in CD138<sup>+</sup> cells, the cohort of patients expressing high levels of <italic>GADD45B</italic> exhibited dramatically shorter progression-free survival and significantly shorter overall survival (OS) than the cohort of patients expressing low levels of <italic>GADD45B</italic>, despite both groups of patients having been treated with the same velcade/melphalan/prednisone protocol (<xref rid="bib27" ref-type="bibr">Palumbo et&#x000a0;al., 2010</xref>) (<xref rid="fig1" ref-type="fig">Figures 1</xref>B and 1C). A similar correlation of <italic>GADD45B</italic> expression with poor clinical outcome was observed using two independent gene expression data sets of newly diagnosed MM patients, thus providing external validation of our findings (<xref rid="bib4 bib12" ref-type="bibr">Broyl et&#x000a0;al., 2010; Dickens et&#x000a0;al., 2010</xref>) (<xref rid="app2" ref-type="sec">Figures S1</xref>A and S1B available online). Collectively, these results establish a strong correlation between <italic>GADD45B</italic> expression and disease progression in MM and identify GADD45&#x003b2; as a hallmark of more aggressive disease.</p></sec><sec id="sec3.2"><title>Constitutive NF-&#x003ba;B Activity Promotes the Survival of MM Cells by Inhibiting JNK Signaling</title><p>GADD45&#x003b2; inhibits apoptosis by suppressing JNK signaling. It mediates this function by binding to the JNK kinase MKK7 and blocking its enzymatic activity by engaging the kinase catalytic pocket (<xref rid="bib28 bib29" ref-type="bibr">Papa et&#x000a0;al., 2004, 2007</xref>). This activity of GADD45&#x003b2; on the JNK pathway and the elevated <italic>GADD45B</italic> mRNA levels observed in monoclonal PCs from MM patients (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A) prompted us to investigate whether GADD45&#x003b2; mediated an antiapoptotic crosstalk between the NF-&#x003ba;B and JNK pathways in MM cells. We reasoned that cell extrinsic stimulation, as well as intrinsic oncogenic signals and NF-&#x003ba;B-pathway mutations, could result in the activation of signaling pathways beyond the IKK/NF-&#x003ba;B cascade, such as the JNK pathway (<xref rid="bib9" ref-type="bibr">Davies and Tournier, 2012</xref>), which we and others have previously shown can trigger apoptosis in a manner that can be suppressed by NF-&#x003ba;B (<xref rid="bib11 bib38 bib28" ref-type="bibr">De Smaele et&#x000a0;al., 2001; Tang et&#x000a0;al., 2001; Papa et&#x000a0;al., 2004</xref>). Indeed, at least in principle, this mechanism could provide a basis for the addiction of MM cells to NF-&#x003ba;B for survival. In line with this hypothesis, in each of five heterogeneous MM cell lines and a B lymphoblastoid cell line, the silencing of the NF-&#x003ba;B subunit RelA (<xref rid="bib13" ref-type="bibr">DiDonato et&#x000a0;al., 2012</xref>) triggered JNK activation and apoptosis (<xref rid="app2" ref-type="sec">Figures S2</xref>A&#x02013;S2C), and blocking this activation with the JNK inhibitor SP600125 effectively protected NF-&#x003ba;B/RelA-silenced MM cells from cell death (<xref rid="app2" ref-type="sec">Figures S2</xref>D and S2E). Similarly, the small hairpin RNA (shRNA)-mediated silencing of MKK7 rescued MM cells from the cytotoxic effects of each of two pharmacological inhibitors of IKK&#x003b2;/NF-&#x003ba;B, and the protective effect of this silencing was virtually complete (<xref rid="app2" ref-type="sec">Figure&#x000a0;S2</xref>F). Collectively, these data indicate that constitutive NF-&#x003ba;B activity promotes the survival of MM cells by inhibiting MKK7/JNK signaling.</p></sec><sec id="sec3.3"><title>GADD45&#x003b2; as a Pivotal Survival Factor Downstream of NF-&#x003ba;B and a Potential Therapeutic Target in MM</title><p>To investigate the possible contribution of GADD45&#x003b2; to MM pathogenesis, we examined whether GADD45&#x003b2; mediated the NF-&#x003ba;B-dependent survival function and inhibition of JNK signaling in MM cells. As with PCs from patients (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A), <italic>GADD45B</italic> was expressed at high levels in MM cell lines compared with most other cancer cell lines tested (<xref rid="app2" ref-type="sec">Figure&#x000a0;S2</xref>G, discussed below). Importantly, this high <italic>GADD45B</italic> expression in MM cells markedly diminished upon the silencing of RelA, thus demonstrating its dependence on constitutive NF-&#x003ba;B activity (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A; <xref rid="app2" ref-type="sec">Figure&#x000a0;S2</xref>C). Moreover, similar to the effects of RelA-targeting hairpins (<xref rid="app2" ref-type="sec">Figures S2</xref>A&#x02013;S2C), the introduction of GADD45&#x003b2;-specific shRNAs, but not of MKK7-specific or of nonspecific shRNAs, induced potent JNK activation and apoptosis in all but two of the MM cell lines tested, namely, the RPMI-8226 and KMM-1 cell lines, which exhibited almost undetectable levels of GADD45&#x003b2; and significantly lower levels of MKK7 than those GADD45&#x003b2;-dependent MM cell lines (<xref rid="fig2" ref-type="fig">Figures 2</xref>B and 2C; <xref rid="app2" ref-type="sec">Figures S2</xref>G&#x02013;S2K, further discussed below). Similar results were observed using additional GADD45&#x003b2;-targeting hairpins, thus confirming the gene-silencing efficiency and specificity of the shRNAs used (<xref rid="app2" ref-type="sec">Figures S2</xref>H, S2J, S2L, and S2M). Strikingly, the extent of JNK activation induced by the silencing of GADD45&#x003b2; in sensitive MM cell lines was similar to that observed with 12-O-tetradecanoylphorbol-13-acetate (TPA)/ionomycin stimulation, which potently induces JNK (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>C; <xref rid="app2" ref-type="sec">Figures S2</xref>I and S2J). By contrast, GADD45&#x003b2; downregulation had no effect on IKK/NF-&#x003ba;B, ERK, or p38 activity. As seen with the inhibition of IKK&#x003b2;/NF-&#x003ba;B (<xref rid="app2" ref-type="sec">Figures S2</xref>D and S2E), both the silencing of JNK1 and the treatment with SP600125 effectively reversed apoptosis in GADD45&#x003b2;-silenced MM cells (<xref rid="fig2" ref-type="fig">Figures 2</xref>D and 2E; <xref rid="app2" ref-type="sec">Figures S2</xref>N&#x02013;S2P). Hence, GADD45&#x003b2; promotes the survival of MM cells by inhibiting JNK-mediated apoptosis. Collectively, these findings identify GADD45&#x003b2; as an essential NF-&#x003ba;B-regulated survival factor and selective MKK7/JNK-axis inhibitor and, therefore, as a potential therapeutic target in MM.</p></sec><sec id="sec3.4"><title>Development of D-Tetrapeptide Inhibitors of the GADD45&#x003b2;/MKK7 Complex</title><p>Given the essential antiapoptotic role of GADD45&#x003b2; in MM and our previous results showing that GADD45&#x003b2; suppresses JNK signaling and apoptosis by blocking MKK7 via direct physical interaction (<xref rid="bib11 bib28 bib29" ref-type="bibr">De Smaele et&#x000a0;al., 2001; Papa et&#x000a0;al., 2004, 2007</xref>), we aimed to develop selective inhibitors of this protein-protein interaction in order to induce cytotoxic JNK signaling in MM cells. We screened a simplified combinatorial library of 20,736 L-tetrapeptides to select compounds capable of disrupting the GADD45&#x003b2;/MKK7 complex (<xref rid="app2" ref-type="sec">Figure&#x000a0;S3</xref>A and <xref rid="app2" ref-type="sec">Table S1</xref>). Iterative deconvolution of this library in ELISA competition assays, followed by secondary screening and optimization of the resulting hits, yielded two <italic>ac</italic>etylated L-<italic>t</italic>etra<italic>p</italic>eptides of similar structure, namely, Ac-LTP1 and Ac-LTP2, which disrupted the GADD45&#x003b2;/MKK7 complex, in&#x000a0;vitro, with remarkable half-maximal inhibitory concentration (IC<sub>50</sub>) values in the subnanomolar range (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A; <xref rid="app2" ref-type="sec">Figure&#x000a0;S3</xref>B and <xref rid="app2" ref-type="sec">Table S2</xref>), in line with the top-end potencies of other hits isolated from similar peptide library screens (<xref rid="bib16" ref-type="bibr">Houghten et&#x000a0;al., 1999</xref>).</p><p>Next, we examined whether these two L-tetrapeptides retained in&#x000a0;vitro potency upon synthesis in the D configuration, a strategy used successfully in some cases to render small peptides resistant to proteolysis (<xref rid="bib43 bib26" ref-type="bibr">Zhou et&#x000a0;al., 2002; Nickl et&#x000a0;al., 2010</xref>). Strikingly, as shown in <xref rid="fig3" ref-type="fig">Figures 3</xref>A and 3B, the D-enantiomers of Ac-LTP1 and Ac-LTP2 (termed Ac-DTP1 and Ac-DTP2, respectively) displayed no loss of activity in&#x000a0;vitro and, unlike their L counterparts, were highly stable in human serum, even after prolonged incubation. Coimmunoprecipitation assays confirmed the potent and specific inhibitory effect of Ac-DTP1 and Ac-DTP2 on GADD45&#x003b2;/MKK7 complex stability in&#x000a0;vitro (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>C). By contrast, control D-tetrapeptides had no such effect on stability, thus demonstrating the specificity of the inhibitory activities of Ac-DTP1 and Ac-DTP2. Crucially, the disruption of the complex by these two active D-peptides completely reversed the GADD45&#x003b2;-mediated inhibition of MKK7, fully restoring the kinase catalytic activity (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>D, top). Importantly, none of Ac-DTP1, Ac-DTP2, or any of the control D-tetrapeptides affected MKK7 activity in the absence of GADD45&#x003b2; (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>D, bottom). Collectively, these findings identify a downstream, drug-targetable module in the NF-&#x003ba;B pathway and confirm the potential of our pharmacological approach for inducing cytotoxic MKK7/JNK signaling in cells that rely on GADD45&#x003b2; for restraining MKK7 activation.</p><p>To verify the therapeutic potential of GADD45&#x003b2;/MKK7 inhibitors, we aimed to improve their cell penetration. We replaced the N-terminal acetyl group of Ac-DTP1 and Ac-DTP2 with a benzyloxycarbonyl [Z] group, thereby generating z-DTP1 and z-DTP2, respectively (<xref rid="app2" ref-type="sec">Table S3</xref>), which retained high activity and stability in&#x000a0;vitro (<xref rid="app2" ref-type="sec">Figures S4</xref>A and S4B) and, importantly, also exhibited potent cytotoxic activity across a panel of genetically heterogeneous MM cell lines (<xref rid="fig4" ref-type="fig">Figures 4</xref>A and 4B; <xref rid="app2" ref-type="sec">Figures S4</xref>C&#x02013;S4F and <xref rid="app2" ref-type="sec">Table S3</xref>). Significantly, z-DTP1 and z-DTP2, but not a control D-tetrapeptide, induced potent and dose-dependent toxicity in all of the MM cell lines tested, except the two expressing nearly undetectable levels of <italic>GADD45B</italic> and low levels of MKK7 (further discussed below), exhibiting IC<sub>50</sub> values in the sensitive MM cell lines in the low nanomolar to low micromolar range (<xref rid="fig4" ref-type="fig">Figures 4</xref>A and 4B; <xref rid="app2" ref-type="sec">Figures S2</xref>G, <xref rid="app2" ref-type="sec">S4</xref>E, and S4F). Consistent with the protective mechanism mediated by GADD45&#x003b2; (<xref rid="app2" ref-type="sec">Figure&#x000a0;S2</xref>G), the z-DTP1- and z-DTP2-afforded killing of sensitive MM cells was due to the induction of apoptosis (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>C; <xref rid="app2" ref-type="sec">Figures S4</xref>G and S4H). Importantly, both active D-peptides retained potent and cancer-selective activity in primary PCs from MM patients (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>D, left). Crucially, these D-peptides also exhibited an apparently complete lack of toxicity to normal cells, even when used at very high concentrations (i.e., 100&#x000a0;&#x003bc;M; <xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>D, right; <xref rid="app2" ref-type="sec">Figure&#x000a0;S4</xref>I). Hence, D-tetrapeptide antagonists of the GADD45&#x003b2;/MKK7 complex show exceptionally high activity and cancer cell specificity in terms of apoptosis induction in MM cells, without displaying any apparent toxicity to normal cells.</p></sec><sec id="sec3.5"><title>The Development of DTP3: A GADD45&#x003b2;/MKK7 Inhibitor with Improved Bioavailability</title><p>To improve the bioavailability of <sc>D</sc>-peptides in&#x000a0;vivo, while retaining high cellular activity and specificity toward the GADD45&#x003b2;/MKK7 complex, we used a chemical optimization strategy based on structure-activity relationship and pharmacophore analyses (<xref rid="app2" ref-type="sec">Figures S5</xref>A&#x02013;S5C and <xref rid="app2" ref-type="sec">Table S4</xref>). By combining these methods, we developed DTP3, a D-tripeptide with a molecular weight of 525&#x000a0;Da (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A), which retained all the main characteristics of the parental D-tetrapeptides in terms of bioactivity and specificity, including subnanomolar activity and high stability in&#x000a0;vitro and potent and selective capacity to kill MM cells via apoptosis (<xref rid="app2" ref-type="sec">Figures S5</xref>D&#x02013;S5H), while exhibiting a superior pharmacokinetic profile compared with the parent molecules (discussed below).</p><p>We further evaluated the modality and specificity of the binding of DTP3 to the GADD45&#x003b2;/MKK7 complex. Circular dichroism (CD) studies demonstrated that DTP3, but not a control scrambled (SCRB) D-tripeptide, can physically interact with and cause a significant conformational change of the structure of this complex, as well as of the isolated MKK7 protein, in a dose-dependent manner (<xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>I). By contrast, DTP3 had no effect on the CD signal of GADD45&#x003b2; (<xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>I). MALDI-TOF mass spectrometry confirmed the ability of DTP3 to bind to MKK7, but not to GADD45&#x003b2; (<xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>J). Spectrofluorimetric analyses yielded similar results and, furthermore, established the 1:1 stoichiometry and low equilibrium dissociation constant (<italic>K</italic><sub>D</sub>) value of the DTP3 interaction with MKK7 (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>B; <xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>K), thus underscoring the strength and specificity of this interaction. Conversely, the SCRB D-tripeptide had no impact on the fluorescence emission spectrum of MKK7, thus reaffirming the specificity of the effects of DTP3. Computational analyses predicted the presence of a pocket of MKK7, also found on the GADD45&#x003b2;/MKK7 complex, that can bind to DTP3 (<xref rid="app2" ref-type="sec">Figures S5</xref>L&#x02013;S5T). Collectively, these results demonstrate that DTP3 has the capacity to physically interact with MKK7, both in isolation and within the complex with GADD45&#x003b2;, and support a&#x000a0;model whereby, upon binding to MKK7, DTP3 dissociates the GADD45&#x003b2;/MKK7 complex via an allosteric mechanism, potentially involving a conformational rearrangement of the kinase.</p></sec><sec id="sec3.6"><title>The High Target Specificity of DTP3 for the GADD45&#x003b2;/MKK7 Complex</title><p>In a panel of tumor cell lines of different tissues of origin, the sensitivity to DTP3-induced killing correlated with a very high degree of significance with the mRNA levels of <italic>GADD45B</italic> (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>C; <xref rid="app2" ref-type="sec">Figures S2</xref>G and <xref rid="app2" ref-type="sec">S5</xref>U), which our data have shown is a pivotal NF-&#x003ba;B-regulated inhibitor of MKK7/JNK signaling and apoptosis in MM cells (<xref rid="fig2" ref-type="fig">Figures 2</xref>B&#x02013;2E; <xref rid="app2" ref-type="sec">Figures S2</xref>H&#x02013;S2J and S2N&#x02013;S2P). Significantly, DTP3 displayed potent and selective activity in both MM and non-MM cell lines exhibiting high levels of <italic>GADD45B</italic> expression, whereas it was completely inactive, even at high micromolar concentrations, in tumor cell lines featuring low <italic>GADD45B</italic> expression (<xref rid="app2" ref-type="sec">Figures S2</xref>G and <xref rid="app2" ref-type="sec">S5</xref>F&#x02013;S5H). In the context of MM, the RPMI-8226 and KMM-1 cell lines, which express very low levels of GADD45&#x003b2; and low levels of MKK7 and are consequently unaffected by GADD45&#x003b2;-targeting hairpins, were completely refractory to DTP3-induced killing (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B; <xref rid="app2" ref-type="sec">Figures S2</xref>G&#x02013;S2I, S2K, and <xref rid="app2" ref-type="sec">S5</xref>F&#x02013;S5H).</p><p>As seen with GADD45&#x003b2;-silencing shRNAs (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>C; <xref rid="app2" ref-type="sec">Figures S2</xref>H and S2I), treatment with DTP3 effectively activated JNK but not p38, ERK, or IKK/NF-&#x003ba;B signaling in sensitive, GADD45&#x003b2;-dependent MM cell lines, whereas it did not affect any of these pathways in DTP3-resistant, GADD45&#x003b2;-independent MM cell lines, such as RPMI-8226 (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>D; <xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>V; see also <xref rid="app2" ref-type="sec">Figure&#x000a0;S4</xref>H, z-DTP2). Strikingly, the magnitude of the effects of DTP3 on the JNK pathway was similar to that observed with tumor necrosis factor &#x003b1; (TNF&#x003b1;), a potent inducer of JNK (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>D; <xref rid="app2" ref-type="sec">Figures S4</xref>H and <xref rid="app2" ref-type="sec">S5</xref>V, TPA/ionomycin). By contrast, a negative control D-peptide had no effect on JNK signaling (<xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>V). As expected from the in&#x000a0;vitro data (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>B; <xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>I, middle, bottom; <xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>J, left), these activating effects of DTP3 on the JNK pathway hinged upon the ability of this D-tripeptide to bind to MKK7 in cells, as shown by DTP3 pull-down assays (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>E). These effects were not observed with the SCRB control peptide, nor were they observed with a pull-down control in the absence of peptide, thus demonstrating the specificity of the binding of DTP3 to endogenous MKK7. Importantly, knocking down the GADD45&#x003b2; target kinase, MKK7, or its downstream effector, JNK1, completely abolished the cytotoxic activity of DTP3 in sensitive MM cell lines (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>F; <xref rid="app2" ref-type="sec">Figures S5</xref>W and S5X), thus excluding any off-target toxicity of DTP3 in cells. DTP3 also lacked any off-target effect when profiled in kinase assays against a panel of 142 human kinases (<xref rid="app2" ref-type="sec">Table S5</xref>). Hence, bioactive D-peptides selectively induce apoptosis in MM cells with functional MKK7 and elevated GADD45&#x003b2; expression by activating JNK signaling via MKK7. These findings also correlate the pharmacological activity of DTP3 with a tumor cell dependence on GADD45&#x003b2; for survival and establish the exceptionally high target specificity of this D-tripeptide for the GADD45&#x003b2;/MKK7 complex in cells.</p></sec><sec id="sec3.7"><title>The Potent and Cancer-Selective Activity of DTP3 in MM Cells from Patients</title><p>To verify the suitability of DTP3 for the treatment of human diseases, we tested its activity and selectivity in MM PCs from patients. As seen with the active D-tetrapeptides (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>D, left), DTP3 effectively killed primary MM PCs at low nanomolar concentrations (<xref rid="fig6" ref-type="fig">Figures 6</xref>A and 6B). Importantly, it retained potent and selective cytotoxic activity in these cells upon stimulation with interleukin-6 or insulin growth factor 1 or coculture with bone marrow stromal cells (BMSCs) (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>C; <xref rid="app2" ref-type="sec">Figures S6</xref>A and S6B), which promote the survival of MM cells (<xref rid="bib15" ref-type="bibr">Hideshima et&#x000a0;al., 2005</xref>). In order to compare the efficacy and cancer cell specificity of DTP3 with the corresponding parameters of bortezomib, the current gold-standard treatment for MM (<xref rid="bib6" ref-type="bibr">Chen et&#x000a0;al., 2011</xref>), we defined an &#x0201c;in&#x000a0;vitro therapeutic index&#x0201d; (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>A, bottom). As shown in <xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>A (top), DTP3 had a similar IC<sub>50</sub> value to bortezomib in primary MM PCs but, importantly, unlike bortezomib, which barely discriminated between malignant and normal cells, had no toxicity to normal cells. Strikingly, because of this cancer cell selective target specificity, DTP3 had an in&#x000a0;vitro therapeutic index that was greater, by more than two orders of magnitude, than that of bortezomib (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>A, bottom). DTP3, in fact, could also distinguish between PCs from MM and Waldenstr&#x000f6;m&#x02019;s macroglobulinemia (WM) patients (<xref rid="bib19" ref-type="bibr">Kyle and Rajkumar, 2009</xref>), in line with the <italic>GADD45B</italic> expression levels in these cells, whereas bortezomib could not (<xref rid="fig6" ref-type="fig">Figures 6</xref>A and 6B; <xref rid="app2" ref-type="sec">Figure&#x000a0;S6</xref>C). Similarly, DTP3 displayed far more potent activity in primary MM PCs and far less toxicity to normal cells than the IKK&#x003b2; inhibitor, PS-1145 (<xref rid="fig6" ref-type="fig">Figures 6</xref>C and 6D; <xref rid="app2" ref-type="sec">Figures S6</xref>A and S6B; note the different concentrations of DTP3 and PS-1145 used). Because the standard MM treatment consists of combination therapy, and nearly all patients will relapse and/or develop drug resistance at some point, we evaluated the potential of DTP3 to operate in these settings. As shown in <xref rid="app2" ref-type="sec">Figures S6</xref>D and S6E, DTP3 displayed synergistic activity with bortezomib in two different MM cell lines, exhibiting a combination index of 0.21 in U266 cells and of 0.56 in KMS-12 cells, suggesting that it could find indication in the clinic in combination with bortezomib (<xref rid="bib8" ref-type="bibr">Chou, 2006</xref>). Importantly, DTP3 also retained full therapeutic efficacy in MM cell lines that were resistant to conventional MM treatments, such as dexamethasone, bortezomib, and lenalidomide (<xref rid="bib2 bib3 bib35" ref-type="bibr">Bjorklund et&#x000a0;al., 2011, 2014, R&#x000fc;ckrich et&#x000a0;al., 2009</xref>) (<xref rid="app2" ref-type="sec">Figures S6</xref>F and S6G). Together, these results provide compelling evidence of the high therapeutic potential of DTP3 in MM patients.</p></sec><sec id="sec3.8"><title>The Potent Therapeutic Efficacy and Excellent Tolerability of DTP3 against MM In&#x000a0;Vivo</title><p>DTP3 showed high aqueous solubility and very high stability in human serum, owing to its resistance to proteolysis, with a good pharmacokinetic profile and excellent in&#x000a0;vivo tolerability, suitable for a therapeutic purpose (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>A; <xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref>D and <xref rid="app2" ref-type="sec">Table S6</xref>).</p><p>Remarkably, in a plasmacytoma model, treatment with DTP3 at the dose of 14.5&#x000a0;mg/kg/day virtually eradicated established subcutaneous myeloma xenografts in mice, in the absence of any apparent side effects (<xref rid="fig7" ref-type="fig">Figures 7</xref>B and 7C; <xref rid="app2" ref-type="sec">Figure&#x000a0;S7</xref>A and <xref rid="app2" ref-type="sec">Table S6</xref>). Similar results were obtained in a second plasmacytoma model, generated using a different MM cell line (<xref rid="app2" ref-type="sec">Figures S7</xref>C and S7D). At the experimental end point, on day 28, all the control mice had developed large local tumors, whereas all the mice in the DTP3-treated cohort had shown a dramatic shrinkage of the tumors (<xref rid="fig7" ref-type="fig">Figures 7</xref>B and 7C; <xref rid="app2" ref-type="sec">Figures S7</xref>C and S7D). This therapeutic effect of DTP3 was due to the potent and tumor-selective induction of JNK activation and apoptosis (<xref rid="fig7" ref-type="fig">Figures 7</xref>D and 7E; <xref rid="app2" ref-type="sec">Figure&#x000a0;S7</xref>B), as shown by the appearance of phosphorylated JNK, as early as 24&#x000a0;hr of the onset of treatment with DTP3, but not with PBS, followed by the appearance, starting on day 3, of caspase-3 and PARP-1 proteolysis products. Coincident with these events, apoptotic cells became evident in the tumor tissue at day 3 (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>D; <xref rid="app2" ref-type="sec">Figure&#x000a0;S7</xref>B). As&#x000a0;well as the tumor-ablative effects of DTP3 (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>B; <xref rid="app2" ref-type="sec">Figure&#x000a0;S7</xref>A), the extent of this JNK-associated, tumor cell apoptosis markedly increased in magnitude over time (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>D; <xref rid="app2" ref-type="sec">Figure&#x000a0;S7</xref>B).</p><p>Importantly, DTP3 retained potent anticancer activity in an orthotopic xenograft model of MM, which more faithfully recapitulates the human disease. All the control mice developed severe limb paralysis and died within 32&#x000a0;days of treatment start,&#x000a0;resulting in a median OS of 26&#x000a0;days (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>F). Strikingly, DTP3 administration over a period of 8&#x000a0;weeks, at a dose of 29&#x000a0;mg/kg/day, extended the median OS of the mice past the experimental end point on day 161, without producing any apparent side effect, thus demonstrating the potent therapeutic efficacy of DTP3 against MM, in&#x000a0;vivo, and the excellent tolerability of this agent at doses that achieve full therapeutic efficacy. Collectively, together with the data in primary MM cells (<xref rid="fig6" ref-type="fig">Figures 6</xref>A&#x02013;6D; <xref rid="app2" ref-type="sec">Figures S6</xref>A and S6B), these results underscore the potency, safety, and cancer cell specificity of the pharmacological approach targeting the GADD45&#x003b2;/MKK7 complex in MM and identify DTP3 as a therapeutic selectively inhibiting the NF-&#x003ba;B survival pathway in cancer (<xref rid="fig8" ref-type="fig">Figure&#x000a0;8</xref>).</p></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>We identified the GADD45&#x003b2;/MKK7 complex as a functionally critical survival module downstream of NF-&#x003ba;B and a therapeutic target in MM. Further, we developed a corresponding D-tripeptide inhibitor of this complex, DTP3, which effectively kills MM cells by inducing MKK7/JNK-dependent apoptosis and, at the same time, does not appear to be toxic to normal tissues. Because of this cancer cell specificity, DTP3 displays an exceptionally high therapeutic index in&#x000a0;vitro and potent and cancer-selective&#x000a0;activity against MM in&#x000a0;vivo. Future studies will clarify the precise mechanism by which DTP3 dissociates the GADD45&#x003b2;/MKK7 complex. Notwithstanding, our findings uncover a mechanism for the pathogenetic survival activity of NF-&#x003ba;B in MM. Crucially, they also demonstrate that cancer-selective inhibition of the NF-&#x003ba;B survival pathway is possible and provide a promising therapy with no preclusive toxicity that could be of profound benefit for patients with this cancer and, potentially, others for which NF-&#x003ba;B promotes survival via GADD45&#x003b2; (<xref rid="bib20 bib25 bib40" ref-type="bibr">Lam et&#x000a0;al., 2005; Ngo et&#x000a0;al., 2006; Tracey et&#x000a0;al., 2005</xref>).</p><p>The therapeutic targeting of the NF-&#x003ba;B pathway has been aggressively pursued for the treatment of a wide range of inflammatory and malignant pathologies, including MM (<xref rid="bib13" ref-type="bibr">DiDonato et&#x000a0;al., 2012</xref>). However, it has proved so far an insurmountable challenge. Current therapeutic approaches, such as IKK&#x003b2; inhibitors, target core components of this pathway, and so, although they are potentially capable of abrogating the cancer-promoting activities of NF-&#x003ba;B, they fail to preserve its pleiotropic physiological functions, such as functions in immunity and inflammation (<xref rid="bib37 bib13" ref-type="bibr">Staudt, 2010; DiDonato et&#x000a0;al., 2012</xref>). Because the best documented function of NF-&#x003ba;B in cancer is to induce genes that block apoptosis and, despite its ubiquitous nature, NF-&#x003ba;B signaling elicits highly tissue- and context-specific transcriptional programs (<xref rid="bib13" ref-type="bibr">DiDonato et&#x000a0;al., 2012</xref>), we sought to develop a therapeutic approach capable of inhibiting the NF-&#x003ba;B antiapoptotic activity, in a cancer-selective manner. We reasoned that agents targeting a nonredundant, downstream module within this critical survival axis of the NF-&#x003ba;B pathway and having functional restriction to the cancer cells (e.g., the GADD45&#x003b2;/MKK7 module in the case of MM) would provide a more selective and, therefore, more effective therapy, lacking the dose-limiting toxicities of conventional drugs globally targeting NF-&#x003ba;B. It is noteworthy in this regard that most normal cells do not express <italic>GADD45B</italic> constitutively (<xref rid="bib42" ref-type="bibr">Zhang et&#x000a0;al., 2005</xref>). Furthermore, unlike mice lacking RelA or any subunit of the IKK complex (<xref rid="bib13" ref-type="bibr">DiDonato et&#x000a0;al., 2012</xref>), <italic>Gadd45b</italic><sup>&#x02212;/&#x02212;</sup> mice are viable, are fertile, and die of old age (<xref rid="bib30 bib21" ref-type="bibr">Papa et&#x000a0;al., 2008; Lu et&#x000a0;al., 2004</xref>), indicating that, in contrast to global NF-&#x003ba;B blockade, complete GADD45&#x003b2; inactivation is well tolerated in&#x000a0;vivo.</p><p>Our approach also aims at exploiting the general good safety of peptide therapeutics and the greater selectivity afforded by inhibiting a protein-protein interaction, rather than the entire function of a receptor or an enzyme, as is the case for most drugs. Because of this property and their unique mode of action, it is expected that the side effects of GADD45&#x003b2;/MKK7 inhibitors in patients will be milder than the phenotypes of <italic>Gadd45b</italic><sup>&#x02212;/&#x02212;</sup> mice (<xref rid="bib30 bib21" ref-type="bibr">Papa et&#x000a0;al., 2008; Lu et&#x000a0;al., 2004</xref>), both because of the transient nature of chemotherapeutic treatments and because these agents would enable GADD45&#x003b2; to retain its MKK7-independent functions. The partially impaired T<sub>H</sub>1 T&#x000a0;cell response reported in <italic>Gadd45b</italic><sup>&#x02212;/&#x02212;</sup> mice (<xref rid="bib21" ref-type="bibr">Lu et&#x000a0;al., 2004</xref>), for example, was shown to depend on the Gadd45&#x003b2;-afforded regulation of the MAP3K, MEKK4 (<xref rid="bib7" ref-type="bibr">Chi et&#x000a0;al., 2004</xref>), but not of MKK7. Similarly, such agents would enable MKK7 to retain its enzymatic function and GADD45&#x003b2;-independent modalities of regulation. Nevertheless, future studies will be required to address the potential side effects of DTP3 in patients.</p><p>Many cancers beyond MM rely on constitutive NF-&#x003ba;B signaling for survival (<xref rid="bib37 bib13" ref-type="bibr">Staudt, 2010; DiDonato et&#x000a0;al., 2012</xref>). Together, the high expression of <italic>GADD45B</italic> in a subset of these cancers, including diffuse large B cell lymphoma (DLBCL) and other types of lymphoma (<xref rid="bib20 bib25 bib40" ref-type="bibr">Lam et&#x000a0;al., 2005; Ngo et&#x000a0;al., 2006; Tracey et&#x000a0;al., 2005</xref>), and the selective toxicity of DTP3 in DLBCL, Burkitt&#x02019;s lymphoma and promonocytic leukemia cell lines, imply that GADD45&#x003b2;/MKK7 antagonists may have broader therapeutic potential beyond MM, in other areas of unmet need within oncology. By contrast, certain MM cell lines express low levels of GADD45&#x003b2;, as well as of MKK7, and are refractory to DTP3-induced killing. This suggests the existence of GADD45&#x003b2;-independent mechanisms for NF-&#x003ba;B-dependent survival in certain subtypes of MM and, most likely, in other types of malignancy. For instance, BCL-2 family members are possible mediators of such mechanisms, at least in the context of MM (<xref rid="bib14" ref-type="bibr">Gomez-Bougie and Amiot, 2013</xref>). Therefore, on the basis of the principle we describe here of targeting an axis of the NF-&#x003ba;B pathway with cancer-restricted function, rather than NF-&#x003ba;B globally, delineating these mechanisms could provide new strategies for targeting NF-&#x003ba;B in a disease-specific manner also in GADD45&#x003b2;-independent, NF-&#x003ba;B-addicted malignancies and, perhaps, nonmalignant NF-&#x003ba;B-driven pathologies.</p></sec><sec sec-type="methods" id="sec5"><title>Experimental Procedures</title><sec id="sec5.1"><title>Cell Purification and Culture</title><p>Cells were cultured according to standard protocols (<xref rid="bib23 bib31" ref-type="bibr">Mauro et&#x000a0;al., 2011; Piva et&#x000a0;al., 2008</xref>). BMSCs and peripheral blood mononuclear cells (PBMCs) were purified from MM patients or the blood of healthy volunteers, respectively, as reported in <xref rid="bib31" ref-type="bibr">Piva et&#x000a0;al. (2008)</xref>. CD138<sup>+</sup> cells were purified from the bone marrow aspirates of patients using CD138 MicroBeads (Miltenyi Biotech). Patients were recruited at the Hematology Division of &#x0201c;Ospedale San Giovanni Battista&#x0201d; (Turin, Italy) and the Haematology Clinic at Imperial College Healthcare NHS Trust, under the approval of the Ethics Committee of &#x0201c;Ospedale San Giovanni Battista&#x0201d; (VMP-VMPT trial 163) and the London Harrow Research Ethics Committee (11/LO/1628), respectively. Written consent was documented for all subjects. Additional details are provided in <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>.</p></sec><sec id="sec5.2"><title>Biochemical Assays</title><p>Quantitative RT-PCR (qRT-PCR) assays were carried out using the TaqMan Gene Expression Assays kit (Applied Biosystems). The kinase profiling of DTP3 across 142 human kinases was outsourced. Western blots, coimmunoprecipitations, and kinase assays were performed as described previously (<xref rid="bib28 bib30 bib23" ref-type="bibr">Papa et&#x000a0;al., 2004, 2008; Mauro et&#x000a0;al., 2011</xref>). Additional details are provided in <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>.</p></sec><sec id="sec5.3"><title>Cellular Assays</title><p>Lentiviral infections were performed using pLentiLox.3.7, as described by <xref rid="bib23" ref-type="bibr">Mauro et&#x000a0;al. (2011)</xref>. Enhanced GFP (eGFP)<sup>+</sup> cells were purified, when necessary, by fluorescence-activated cell sorting. [<sup>3</sup>H]Thymidine incorporation and trypan blue exclusion assays were performed using standard methods (<xref rid="bib23" ref-type="bibr">Mauro et&#x000a0;al., 2011</xref>). IC<sub>50</sub> values were defined as the mean concentration of compound inducing 50% inhibition of cell viability relative to the viability in the untreated cultures. Apoptosis analyses were performed using propidium iodide (PI) staining, as described by <xref rid="bib23" ref-type="bibr">Mauro et&#x000a0;al. (2011)</xref>. Additional details are provided in <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>.</p></sec><sec id="sec5.4"><title>Peptide Synthesis and ELISA</title><p>Proteins were purified as described by <xref rid="bib39" ref-type="bibr">Tornatore et&#x000a0;al. (2008)</xref>. The combinatorial L-tetrapeptide libraries and individual peptides were synthesized as reported by <xref rid="app2" ref-type="sec">Sandomenico et&#x000a0;al. (2012)</xref>. The methods used to assess peptide identity and purity and deconvolute the tetrapeptide libraries and the ELISA GADD45&#x003b2;/MKK7 competition assays were described previously (<xref rid="bib36 bib39" ref-type="bibr">Sandomenico et&#x000a0;al., 2012; Tornatore et&#x000a0;al., 2008</xref>). IC<sub>50</sub> values were defined as the mean concentration of peptide inducing 50% inhibition of GADD45&#x003b2; binding to MKK7 relative to the binding measured in the absence of peptide. Additional details are provided in <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>.</p></sec><sec id="sec5.5"><title>DTP3 Binding Assays</title><p>The stoichiometry and <italic>K</italic><sub>D</sub> value of the DTP3/MKK7 interaction were determined by tryptophan fluorescence quenching analysis, after fitting the fluorescence data with a nonlinear regression algorithm, as described by <xref rid="bib41" ref-type="bibr">Williamson (2013)</xref>. Additional details are provided in <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>, along with a description of the methods used for CD and MALDI-TOF mass spectrometry analyses and the pull-down of MKK7 from cells with DTP3.</p></sec><sec id="sec5.6"><title>Pharmacophore Analyses and Modeling</title><p>See <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>.</p></sec><sec id="sec5.7"><title>Pharmacokinetic Analyses</title><p>The pharmacokinetic analyses of DTP3 and z-DTP2 were outsourced. Additional details are provided in <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>.</p></sec><sec id="sec5.8"><title>Animal Studies</title><p>Mice were housed in the animal facilities at Hammersmith. All experiments were conducted under Procedure Project License (PPL) 70/6874, after approval by the Imperial College Ethical Review Process and the Home Office. For the plasmacytoma model, nonobese diabetic/severe combined immunodeficiency mice (NOD.CB17-Prkdc<sup>scid</sup>/IcrCrl; Charles River) were injected subcutaneously with 1.0&#x000a0;&#x000d7; 10<sup>7</sup> U266 or KMS-11 MM cells and then randomized into treatment groups and treated by infusion, as shown. Tumor volumes were measured as described by <xref rid="bib23" ref-type="bibr">Mauro et&#x000a0;al. (2011)</xref>. For the orthotopic MM model, mice of the same strain were sublethally irradiated and then injected intravenously with 1.0&#x000a0;&#x000d7; 10<sup>7</sup> KMS-12-BM MM cells, as described by <xref rid="bib32" ref-type="bibr">Rabin et&#x000a0;al. (2007)</xref>. Mice were then randomized into treatment groups and treated by infusion for 8&#x000a0;weeks, as shown. Animals were monitored daily and euthanized on day 161 of treatment start or when they reached any of the end points in the PPL. Additional details are provided in <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>.</p></sec><sec id="sec5.9"><title>Statistical Analyses</title><p>See <xref rid="app2" ref-type="sec">Supplemental Experimental Procedures</xref>.</p></sec></sec><sec sec-type="acknowledgement" id="sec6"><title>Author Contributions</title><p>L.T., G.F., M.R., D.R., C.L. and A.R. designed experiments. L.T., A.S., D.R., C.L., D.C., A.K.T., and A.C. performed experiments. L.T., G.F., M.R., A.S., D.R., C.L., A.R., C.T.-S., D.C., D.D., E.B., M.v.D., P.Z., A.J.-C., A.C., A.T., and A.R. analyzed data. M.B., B.A.W., A.L., C.D., P.S., G.M., A.P., and A.R. contributed clinical samples or key reagents. L.T., A.K.T., and J.D. contributed to mouse studies. G.F. wrote the paper. M.R., L.T., D.R., C.L., A.R., and A.T. contributed to writing the paper. A.S., D.R., and C.L. contributed equally to this work.</p></sec></body><back><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Annunziata</surname><given-names>C.M.</given-names></name><name><surname>Davis</surname><given-names>R.E.</given-names></name><name><surname>Demchenko</surname><given-names>Y.</given-names></name><name><surname>Bellamy</surname><given-names>W.</given-names></name><name><surname>Gabrea</surname><given-names>A.</given-names></name><name><surname>Zhan</surname><given-names>F.</given-names></name><name><surname>Lenz</surname><given-names>G.</given-names></name><name><surname>Hanamura</surname><given-names>I.</given-names></name><name><surname>Wright</surname><given-names>G.</given-names></name><name><surname>Xiao</surname><given-names>W.</given-names></name></person-group><article-title>Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma</article-title><source>Cancer Cell</source><volume>12</volume><year>2007</year><fpage>115</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">17692804</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Bjorklund</surname><given-names>C.C.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Z.Q.</given-names></name><name><surname>Davis</surname><given-names>R.E.</given-names></name><name><surname>Kuhn</surname><given-names>D.J.</given-names></name><name><surname>Kornblau</surname><given-names>S.M.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Shah</surname><given-names>J.J.</given-names></name><name><surname>Orlowski</surname><given-names>R.Z.</given-names></name></person-group><article-title>Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>286</volume><year>2011</year><fpage>11009</fpage><lpage>11020</lpage><pub-id pub-id-type="pmid">21189262</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Bjorklund</surname><given-names>C.C.</given-names></name><name><surname>Baladandayuthapani</surname><given-names>V.</given-names></name><name><surname>Lin</surname><given-names>H.Y.</given-names></name><name><surname>Jones</surname><given-names>R.J.</given-names></name><name><surname>Kuiatse</surname><given-names>I.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Shah</surname><given-names>J.J.</given-names></name><name><surname>Thomas</surname><given-names>S.K.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications</article-title><source>Leukemia</source><volume>28</volume><year>2014</year><fpage>373</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">23760401</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Broyl</surname><given-names>A.</given-names></name><name><surname>Hose</surname><given-names>D.</given-names></name><name><surname>Lokhorst</surname><given-names>H.</given-names></name><name><surname>de Knegt</surname><given-names>Y.</given-names></name><name><surname>Peeters</surname><given-names>J.</given-names></name><name><surname>Jauch</surname><given-names>A.</given-names></name><name><surname>Bertsch</surname><given-names>U.</given-names></name><name><surname>Buijs</surname><given-names>A.</given-names></name><name><surname>Stevens-Kroef</surname><given-names>M.</given-names></name><name><surname>Beverloo</surname><given-names>H.B.</given-names></name></person-group><article-title>Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients</article-title><source>Blood</source><volume>116</volume><year>2010</year><fpage>2543</fpage><lpage>2553</lpage><pub-id pub-id-type="pmid">20574050</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>M.A.</given-names></name><name><surname>Lawrence</surname><given-names>M.S.</given-names></name><name><surname>Keats</surname><given-names>J.J.</given-names></name><name><surname>Cibulskis</surname><given-names>K.</given-names></name><name><surname>Sougnez</surname><given-names>C.</given-names></name><name><surname>Schinzel</surname><given-names>A.C.</given-names></name><name><surname>Harview</surname><given-names>C.L.</given-names></name><name><surname>Brunet</surname><given-names>J.P.</given-names></name><name><surname>Ahmann</surname><given-names>G.J.</given-names></name><name><surname>Adli</surname><given-names>M.</given-names></name></person-group><article-title>Initial genome sequencing and analysis of multiple myeloma</article-title><source>Nature</source><volume>471</volume><year>2011</year><fpage>467</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">21430775</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Frezza</surname><given-names>M.</given-names></name><name><surname>Schmitt</surname><given-names>S.</given-names></name><name><surname>Kanwar</surname><given-names>J.</given-names></name><name><surname>Dou</surname><given-names>Q.P.</given-names></name></person-group><article-title>Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives</article-title><source>Curr. Cancer Drug Targets</source><volume>11</volume><year>2011</year><fpage>239</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">21247388</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name><name><surname>Takekawa</surname><given-names>M.</given-names></name><name><surname>Davis</surname><given-names>R.J.</given-names></name><name><surname>Flavell</surname><given-names>R.A.</given-names></name></person-group><article-title>GADD45&#x003b2;/GADD45&#x003b3; and MEKK4 comprise a genetic pathway mediating STAT4-independent IFN&#x003b3; production in T&#x000a0;cells</article-title><source>EMBO J.</source><volume>23</volume><year>2004</year><fpage>1576</fpage><lpage>1586</lpage><pub-id pub-id-type="pmid">15044949</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>T.C.</given-names></name></person-group><article-title>Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies</article-title><source>Pharmacol. Rev.</source><volume>58</volume><year>2006</year><fpage>621</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">16968952</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>C.</given-names></name><name><surname>Tournier</surname><given-names>C.</given-names></name></person-group><article-title>Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies</article-title><source>Biochem. Soc. Trans.</source><volume>40</volume><year>2012</year><fpage>85</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">22260670</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Demchenko</surname><given-names>Y.N.</given-names></name><name><surname>Glebov</surname><given-names>O.K.</given-names></name><name><surname>Zingone</surname><given-names>A.</given-names></name><name><surname>Keats</surname><given-names>J.J.</given-names></name><name><surname>Bergsagel</surname><given-names>P.L.</given-names></name><name><surname>Kuehl</surname><given-names>W.M.</given-names></name></person-group><article-title>Classical and/or alternative NF-kappaB pathway activation in multiple myeloma</article-title><source>Blood</source><volume>115</volume><year>2010</year><fpage>3541</fpage><lpage>3552</lpage><pub-id pub-id-type="pmid">20053756</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>De Smaele</surname><given-names>E.</given-names></name><name><surname>Zazzeroni</surname><given-names>F.</given-names></name><name><surname>Papa</surname><given-names>S.</given-names></name><name><surname>Nguyen</surname><given-names>D.U.</given-names></name><name><surname>Jin</surname><given-names>R.</given-names></name><name><surname>Jones</surname><given-names>J.</given-names></name><name><surname>Cong</surname><given-names>R.</given-names></name><name><surname>Franzoso</surname><given-names>G.</given-names></name></person-group><article-title>Induction of gadd45&#x003b2; by NF-kappaB downregulates pro-apoptotic JNK signalling</article-title><source>Nature</source><volume>414</volume><year>2001</year><fpage>308</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">11713530</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Dickens</surname><given-names>N.J.</given-names></name><name><surname>Walker</surname><given-names>B.A.</given-names></name><name><surname>Leone</surname><given-names>P.E.</given-names></name><name><surname>Johnson</surname><given-names>D.C.</given-names></name><name><surname>Brito</surname><given-names>J.L.</given-names></name><name><surname>Zeisig</surname><given-names>A.</given-names></name><name><surname>Jenner</surname><given-names>M.W.</given-names></name><name><surname>Boyd</surname><given-names>K.D.</given-names></name><name><surname>Gonzalez</surname><given-names>D.</given-names></name><name><surname>Gregory</surname><given-names>W.M.</given-names></name></person-group><article-title>Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome</article-title><source>Clin. Cancer Res.</source><volume>16</volume><year>2010</year><fpage>1856</fpage><lpage>1864</lpage><pub-id pub-id-type="pmid">20215539</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>DiDonato</surname><given-names>J.A.</given-names></name><name><surname>Mercurio</surname><given-names>F.</given-names></name><name><surname>Karin</surname><given-names>M.</given-names></name></person-group><article-title>NF-&#x003ba;B and the link between inflammation and cancer</article-title><source>Immunol. Rev.</source><volume>246</volume><year>2012</year><fpage>379</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">22435567</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Gomez-Bougie</surname><given-names>P.</given-names></name><name><surname>Amiot</surname><given-names>M.</given-names></name></person-group><article-title>Apoptotic machinery diversity in multiple myeloma molecular subtypes</article-title><source>Front. Immunol.</source><volume>4</volume><year>2013</year><fpage>467</fpage><pub-id pub-id-type="pmid">24391642</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Hideshima</surname><given-names>T.</given-names></name><name><surname>Chauhan</surname><given-names>D.</given-names></name><name><surname>Richardson</surname><given-names>P.</given-names></name><name><surname>Anderson</surname><given-names>K.C.</given-names></name></person-group><article-title>Identification and validation of novel therapeutic targets for multiple myeloma</article-title><source>J.&#x000a0;Clin. Oncol.</source><volume>23</volume><year>2005</year><fpage>6345</fpage><lpage>6350</lpage><pub-id pub-id-type="pmid">16155018</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Houghten</surname><given-names>R.A.</given-names></name><name><surname>Pinilla</surname><given-names>C.</given-names></name><name><surname>Appel</surname><given-names>J.R.</given-names></name><name><surname>Blondelle</surname><given-names>S.E.</given-names></name><name><surname>Dooley</surname><given-names>C.T.</given-names></name><name><surname>Eichler</surname><given-names>J.</given-names></name><name><surname>Nefzi</surname><given-names>A.</given-names></name><name><surname>Ostresh</surname><given-names>J.M.</given-names></name></person-group><article-title>Mixture-based synthetic combinatorial libraries</article-title><source>J.&#x000a0;Med. Chem.</source><volume>42</volume><year>1999</year><fpage>3743</fpage><lpage>3778</lpage><pub-id pub-id-type="pmid">10508425</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Keats</surname><given-names>J.J.</given-names></name><name><surname>Fonseca</surname><given-names>R.</given-names></name><name><surname>Chesi</surname><given-names>M.</given-names></name><name><surname>Schop</surname><given-names>R.</given-names></name><name><surname>Baker</surname><given-names>A.</given-names></name><name><surname>Chng</surname><given-names>W.J.</given-names></name><name><surname>Van Wier</surname><given-names>S.</given-names></name><name><surname>Tiedemann</surname><given-names>R.</given-names></name><name><surname>Shi</surname><given-names>C.X.</given-names></name><name><surname>Sebag</surname><given-names>M.</given-names></name></person-group><article-title>Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma</article-title><source>Cancer Cell</source><volume>12</volume><year>2007</year><fpage>131</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">17692805</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Kuehl</surname><given-names>W.M.</given-names></name><name><surname>Bergsagel</surname><given-names>P.L.</given-names></name></person-group><article-title>Multiple myeloma: evolving genetic events and host interactions</article-title><source>Nat. Rev. Cancer</source><volume>2</volume><year>2002</year><fpage>175</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">11990854</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Kyle</surname><given-names>R.A.</given-names></name><name><surname>Rajkumar</surname><given-names>S.V.</given-names></name></person-group><article-title>Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma</article-title><source>Leukemia</source><volume>23</volume><year>2009</year><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18971951</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>L.T.</given-names></name><name><surname>Davis</surname><given-names>R.E.</given-names></name><name><surname>Pierce</surname><given-names>J.</given-names></name><name><surname>Hepperle</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Hottelet</surname><given-names>M.</given-names></name><name><surname>Nong</surname><given-names>Y.</given-names></name><name><surname>Wen</surname><given-names>D.</given-names></name><name><surname>Adams</surname><given-names>J.</given-names></name><name><surname>Dang</surname><given-names>L.</given-names></name><name><surname>Staudt</surname><given-names>L.M.</given-names></name></person-group><article-title>Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling</article-title><source>Clin. Cancer Res.</source><volume>11</volume><year>2005</year><fpage>28</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">15671525</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>B.</given-names></name><name><surname>Ferrandino</surname><given-names>A.F.</given-names></name><name><surname>Flavell</surname><given-names>R.A.</given-names></name></person-group><article-title>Gadd45&#x003b2; is important for perpetuating cognate and inflammatory signals in T&#x000a0;cells</article-title><source>Nat. Immunol.</source><volume>5</volume><year>2004</year><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">14691480</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Mahindra</surname><given-names>A.</given-names></name><name><surname>Laubach</surname><given-names>J.</given-names></name><name><surname>Raje</surname><given-names>N.</given-names></name><name><surname>Munshi</surname><given-names>N.</given-names></name><name><surname>Richardson</surname><given-names>P.G.</given-names></name><name><surname>Anderson</surname><given-names>K.</given-names></name></person-group><article-title>Latest advances and current challenges in the treatment of multiple myeloma</article-title><source>Nat Rev Clin Oncol</source><volume>9</volume><year>2012</year><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">22349016</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Mauro</surname><given-names>C.</given-names></name><name><surname>Leow</surname><given-names>S.C.</given-names></name><name><surname>Anso</surname><given-names>E.</given-names></name><name><surname>Rocha</surname><given-names>S.</given-names></name><name><surname>Thotakura</surname><given-names>A.K.</given-names></name><name><surname>Tornatore</surname><given-names>L.</given-names></name><name><surname>Moretti</surname><given-names>M.</given-names></name><name><surname>De Smaele</surname><given-names>E.</given-names></name><name><surname>Beg</surname><given-names>A.A.</given-names></name><name><surname>Tergaonkar</surname><given-names>V.</given-names></name></person-group><article-title>NF-&#x003ba;B controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration</article-title><source>Nat. Cell Biol.</source><volume>13</volume><year>2011</year><fpage>1272</fpage><lpage>1279</lpage><pub-id pub-id-type="pmid">21968997</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>McCurdy</surname><given-names>A.R.</given-names></name><name><surname>Lacy</surname><given-names>M.Q.</given-names></name></person-group><article-title>Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist</article-title><source>Ther Adv Hematol</source><volume>4</volume><year>2013</year><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">23730498</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>V.N.</given-names></name><name><surname>Davis</surname><given-names>R.E.</given-names></name><name><surname>Lamy</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Lenz</surname><given-names>G.</given-names></name><name><surname>Lam</surname><given-names>L.T.</given-names></name><name><surname>Dave</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Powell</surname><given-names>J.</given-names></name><name><surname>Staudt</surname><given-names>L.M.</given-names></name></person-group><article-title>A loss-of-function RNA interference screen for molecular targets in cancer</article-title><source>Nature</source><volume>441</volume><year>2006</year><fpage>106</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">16572121</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Nickl</surname><given-names>C.K.</given-names></name><name><surname>Raidas</surname><given-names>S.K.</given-names></name><name><surname>Zhao</surname><given-names>H.</given-names></name><name><surname>Sausbier</surname><given-names>M.</given-names></name><name><surname>Ruth</surname><given-names>P.</given-names></name><name><surname>Tegge</surname><given-names>W.</given-names></name><name><surname>Brayden</surname><given-names>J.E.</given-names></name><name><surname>Dostmann</surname><given-names>W.R.</given-names></name></person-group><article-title>(D)-Amino acid analogues of DT-2 as highly selective and superior inhibitors of cGMP-dependent protein kinase Ialpha</article-title><source>Biochim. Biophys. Acta</source><volume>1804</volume><year>2010</year><fpage>524</fpage><lpage>532</lpage><pub-id pub-id-type="pmid">20018259</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Palumbo</surname><given-names>A.</given-names></name><name><surname>Bringhen</surname><given-names>S.</given-names></name><name><surname>Rossi</surname><given-names>D.</given-names></name><name><surname>Cavalli</surname><given-names>M.</given-names></name><name><surname>Larocca</surname><given-names>A.</given-names></name><name><surname>Ria</surname><given-names>R.</given-names></name><name><surname>Offidani</surname><given-names>M.</given-names></name><name><surname>Patriarca</surname><given-names>F.</given-names></name><name><surname>Nozzoli</surname><given-names>C.</given-names></name><name><surname>Guglielmelli</surname><given-names>T.</given-names></name></person-group><article-title>Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial</article-title><source>J.&#x000a0;Clin. Oncol.</source><volume>28</volume><year>2010</year><fpage>5101</fpage><lpage>5109</lpage><pub-id pub-id-type="pmid">20940200</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Papa</surname><given-names>S.</given-names></name><name><surname>Zazzeroni</surname><given-names>F.</given-names></name><name><surname>Bubici</surname><given-names>C.</given-names></name><name><surname>Jayawardena</surname><given-names>S.</given-names></name><name><surname>Alvarez</surname><given-names>K.</given-names></name><name><surname>Matsuda</surname><given-names>S.</given-names></name><name><surname>Nguyen</surname><given-names>D.U.</given-names></name><name><surname>Pham</surname><given-names>C.G.</given-names></name><name><surname>Nelsbach</surname><given-names>A.H.</given-names></name><name><surname>Melis</surname><given-names>T.</given-names></name></person-group><article-title>Gadd45 &#x003b2; mediates the NF-&#x003ba; B suppression of JNK signalling by targeting MKK7/JNKK2</article-title><source>Nat. Cell Biol.</source><volume>6</volume><year>2004</year><fpage>146</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">14743220</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Papa</surname><given-names>S.</given-names></name><name><surname>Monti</surname><given-names>S.M.</given-names></name><name><surname>Vitale</surname><given-names>R.M.</given-names></name><name><surname>Bubici</surname><given-names>C.</given-names></name><name><surname>Jayawardena</surname><given-names>S.</given-names></name><name><surname>Alvarez</surname><given-names>K.</given-names></name><name><surname>De Smaele</surname><given-names>E.</given-names></name><name><surname>Dathan</surname><given-names>N.</given-names></name><name><surname>Pedone</surname><given-names>C.</given-names></name><name><surname>Ruvo</surname><given-names>M.</given-names></name><name><surname>Franzoso</surname><given-names>G.</given-names></name></person-group><article-title>Insights into the structural basis of the GADD45&#x003b2;-mediated inactivation of the JNK kinase, MKK7/JNKK2</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>282</volume><year>2007</year><fpage>19029</fpage><lpage>19041</lpage><pub-id pub-id-type="pmid">17485467</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Papa</surname><given-names>S.</given-names></name><name><surname>Zazzeroni</surname><given-names>F.</given-names></name><name><surname>Fu</surname><given-names>Y.X.</given-names></name><name><surname>Bubici</surname><given-names>C.</given-names></name><name><surname>Alvarez</surname><given-names>K.</given-names></name><name><surname>Dean</surname><given-names>K.</given-names></name><name><surname>Christiansen</surname><given-names>P.A.</given-names></name><name><surname>Anders</surname><given-names>R.A.</given-names></name><name><surname>Franzoso</surname><given-names>G.</given-names></name></person-group><article-title>Gadd45&#x003b2; promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling</article-title><source>J.&#x000a0;Clin. Invest.</source><volume>118</volume><year>2008</year><fpage>1911</fpage><lpage>1923</lpage><pub-id pub-id-type="pmid">18382767</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Piva</surname><given-names>R.</given-names></name><name><surname>Ruggeri</surname><given-names>B.</given-names></name><name><surname>Williams</surname><given-names>M.</given-names></name><name><surname>Costa</surname><given-names>G.</given-names></name><name><surname>Tamagno</surname><given-names>I.</given-names></name><name><surname>Ferrero</surname><given-names>D.</given-names></name><name><surname>Giai</surname><given-names>V.</given-names></name><name><surname>Coscia</surname><given-names>M.</given-names></name><name><surname>Peola</surname><given-names>S.</given-names></name><name><surname>Massaia</surname><given-names>M.</given-names></name></person-group><article-title>CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib</article-title><source>Blood</source><volume>111</volume><year>2008</year><fpage>2765</fpage><lpage>2775</lpage><pub-id pub-id-type="pmid">18057228</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Rabin</surname><given-names>N.</given-names></name><name><surname>Kyriakou</surname><given-names>C.</given-names></name><name><surname>Coulton</surname><given-names>L.</given-names></name><name><surname>Gallagher</surname><given-names>O.M.</given-names></name><name><surname>Buckle</surname><given-names>C.</given-names></name><name><surname>Benjamin</surname><given-names>R.</given-names></name><name><surname>Singh</surname><given-names>N.</given-names></name><name><surname>Glassford</surname><given-names>J.</given-names></name><name><surname>Otsuki</surname><given-names>T.</given-names></name><name><surname>Nathwani</surname><given-names>A.C.</given-names></name></person-group><article-title>A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer</article-title><source>Leukemia</source><volume>21</volume><year>2007</year><fpage>2181</fpage><lpage>2191</lpage><pub-id pub-id-type="pmid">17657224</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Rajkumar</surname><given-names>S.V.</given-names></name></person-group><article-title>Treatment of multiple myeloma</article-title><source>Nat. Rev. Clin. Oncol.</source><volume>8</volume><year>2011</year><fpage>479</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">21522124</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>P.G.</given-names></name></person-group><article-title>Improving the therapeutic index in myeloma</article-title><source>Blood</source><volume>116</volume><year>2010</year><fpage>4733</fpage><lpage>4734</lpage><pub-id pub-id-type="pmid">21127178</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>R&#x000fc;ckrich</surname><given-names>T.</given-names></name><name><surname>Kraus</surname><given-names>M.</given-names></name><name><surname>Gogel</surname><given-names>J.</given-names></name><name><surname>Beck</surname><given-names>A.</given-names></name><name><surname>Ovaa</surname><given-names>H.</given-names></name><name><surname>Verdoes</surname><given-names>M.</given-names></name><name><surname>Overkleeft</surname><given-names>H.S.</given-names></name><name><surname>Kalbacher</surname><given-names>H.</given-names></name><name><surname>Driessen</surname><given-names>C.</given-names></name></person-group><article-title>Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells</article-title><source>Leukemia</source><volume>23</volume><year>2009</year><fpage>1098</fpage><lpage>1105</lpage><pub-id pub-id-type="pmid">19225532</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Sandomenico</surname><given-names>A.</given-names></name><name><surname>Russo</surname><given-names>A.</given-names></name><name><surname>Palmieri</surname><given-names>G.</given-names></name><name><surname>Bergamo</surname><given-names>P.</given-names></name><name><surname>Gogliettino</surname><given-names>M.</given-names></name><name><surname>Falcigno</surname><given-names>L.</given-names></name><name><surname>Ruvo</surname><given-names>M.</given-names></name></person-group><article-title>Small peptide inhibitors of acetyl-peptide hydrolase having an uncommon mechanism of inhibition and a stable bent conformation</article-title><source>J.&#x000a0;Med. Chem.</source><volume>55</volume><year>2012</year><fpage>2102</fpage><lpage>2111</lpage><pub-id pub-id-type="pmid">22309188</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Staudt</surname><given-names>L.M.</given-names></name></person-group><article-title>Oncogenic activation of NF-kappaB</article-title><source>Cold Spring Harb. Perspect. Biol.</source><volume>2</volume><year>2010</year><fpage>a000109</fpage><pub-id pub-id-type="pmid">20516126</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>G.</given-names></name><name><surname>Minemoto</surname><given-names>Y.</given-names></name><name><surname>Dibling</surname><given-names>B.</given-names></name><name><surname>Purcell</surname><given-names>N.H.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Karin</surname><given-names>M.</given-names></name><name><surname>Lin</surname><given-names>A.</given-names></name></person-group><article-title>Inhibition of JNK activation through NF-kappaB target genes</article-title><source>Nature</source><volume>414</volume><year>2001</year><fpage>313</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">11713531</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Tornatore</surname><given-names>L.</given-names></name><name><surname>Marasco</surname><given-names>D.</given-names></name><name><surname>Dathan</surname><given-names>N.</given-names></name><name><surname>Vitale</surname><given-names>R.M.</given-names></name><name><surname>Benedetti</surname><given-names>E.</given-names></name><name><surname>Papa</surname><given-names>S.</given-names></name><name><surname>Franzoso</surname><given-names>G.</given-names></name><name><surname>Ruvo</surname><given-names>M.</given-names></name><name><surname>Monti</surname><given-names>S.M.</given-names></name></person-group><article-title>Gadd45 &#x003b2; forms a homodimeric complex that binds tightly to MKK7</article-title><source>J.&#x000a0;Mol. Biol.</source><volume>378</volume><year>2008</year><fpage>97</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">18343408</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Tracey</surname><given-names>L.</given-names></name><name><surname>P&#x000e9;rez-Rosado</surname><given-names>A.</given-names></name><name><surname>Artiga</surname><given-names>M.J.</given-names></name><name><surname>Camacho</surname><given-names>F.I.</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>A.</given-names></name><name><surname>Mart&#x000ed;nez</surname><given-names>N.</given-names></name><name><surname>Ruiz-Ballesteros</surname><given-names>E.</given-names></name><name><surname>Mollejo</surname><given-names>M.</given-names></name><name><surname>Martinez</surname><given-names>B.</given-names></name><name><surname>Cuadros</surname><given-names>M.</given-names></name></person-group><article-title>Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively</article-title><source>J.&#x000a0;Pathol.</source><volume>206</volume><year>2005</year><fpage>123</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">15880597</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Williamson</surname><given-names>M.P.</given-names></name></person-group><article-title>Using chemical shift perturbation to characterise ligand binding</article-title><source>Prog. Nucl. Magn. Reson. Spectrosc.</source><volume>73</volume><year>2013</year><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">23962882</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Ahsan</surname><given-names>M.H.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Sambucetti</surname><given-names>L.C.</given-names></name><name><surname>Purchio</surname><given-names>A.F.</given-names></name><name><surname>West</surname><given-names>D.B.</given-names></name></person-group><article-title>NF-kappaB and not the MAPK signaling pathway regulates GADD45&#x003b2; expression during acute inflammation</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>280</volume><year>2005</year><fpage>21400</fpage><lpage>21408</lpage><pub-id pub-id-type="pmid">15797874</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>N.</given-names></name><name><surname>Luo</surname><given-names>Z.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>X.</given-names></name><name><surname>Cayabyab</surname><given-names>M.</given-names></name><name><surname>Hiraoka</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Han</surname><given-names>X.</given-names></name><name><surname>Pesavento</surname><given-names>J.</given-names></name><name><surname>Dong</surname><given-names>C.Z.</given-names></name></person-group><article-title>Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>277</volume><year>2002</year><fpage>17476</fpage><lpage>17485</lpage><pub-id pub-id-type="pmid">11880384</pub-id></element-citation></ref></ref-list><sec id="app2" sec-type="supplementary-material"><title>Supplemental Information</title><p><supplementary-material content-type="local-data" id="mmc1"><caption><title>Document S1. Supplemental Experimental Procedures, Figures S1&#x02013;S7, Tables S1&#x02013;S6</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>Document S2. Article plus Supplemental Information</title></caption><media xlink:href="mmc2.pdf"/></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p>We thank G. Inghirami, F. Dazzi, R. Orlowski, I. Kuiatse, L. Bergsagel, H. Auner, K. Parzych, and A. Karadimitris for cell lines; L. De Colibus, A. De Simone, E. Bellone, and M. Gambella for analytical or technical assistance; G. Cruciani for access to FLAP; and P. Omed&#x000e8; for primary PC samples. We also thank A. Iavarone for critical experimental advice and U. Siebenlist, K. Kelly, M. Lenardo, M. Pagano, H. Walczak, G. Acton, L. Busino, A. De Simone, and E. Tate for critical reading of the manuscript. The work was supported in part by Medical Research Council grants G0901436 and MR/L005069/1, NIH grants CA084040 and CA098583, Cancer Research UK grants A8839 and A15115, and an Imperial Innovations grant to G.F.; Project MERIT FIRB No. RBNE08NKH7_003 to M.R.; King Abdullah University of Science and Technology award KUK-I1-012-43 and PRIN 20108XYHJS to A.T.; and a PRIN 2009 grant to A.P.</p><p>G.F., L.T., M.R., C.L., C.T.S., A.J.C., A.P. and A.R. are named inventors on patent applications that have arisen from this research. Some of these authors hold shares in, or retain financial interests relating to, a for-profit company, Kesios Therapeutics, Ltd. G.F. is a Director of Kesios Therapeutics, Ltd. M.R. and L.T. are consultants for Kesios Therapeutics, Ltd.</p></ack></back><floats-group><fig id="fig1"><label>Figure&#x000a0;1</label><caption><p><italic>GADD45B</italic> Is Highly Expressed in MM Cells and Associates with Aggressive Disease</p><p>(A) qRT-PCR showing the <italic>GADD45B</italic> mRNA levels in monoclonal CD138<sup>+</sup> cells from MM or MGUS patients and polyclonal CD138<sup>+</sup> cells (normal). <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;= 0.00018.</p><p>(B and C) Progression-free survival (B) and OS (C), as defined by the International Myeloma Working Group Uniform Response Criteria (<xref rid="bib19" ref-type="bibr">Kyle and Rajkumar, 2009</xref>), in MM patients with low or high <italic>GADD45B</italic> levels, as assessed by qRT-PCR, in CD138<sup>+</sup> cells. Patients were from the velcade/melphalan/prednisone arm of the trial and stratified at diagnosis, using as a cutoff the median <italic>GADD45B</italic> expression value.</p><p>See also <xref rid="app2" ref-type="sec">Figure&#x000a0;S1</xref>.</p></caption><graphic xlink:href="gr1"/></fig><fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>GADD45&#x003b2; Mediates the NF-&#x003ba;B Survival Activity in MM Cells by Suppressing JNK Signaling</p><p>(A) qRT-PCR showing the <italic>GADD45B</italic> mRNA levels in MM cell lines expressing nonspecific (sh-ns) or RelA-specific (sh-RelA) shRNAs. <italic>JNK1</italic> is shown as control. Values denote mean&#x000a0;&#x000b1; SD (n&#x000a0;= 3).</p><p>(B) Survival of MM cell lines expressing sh-ns, GADD45&#x003b2;-specific (sh-GADD45&#x003b2;), or MKK7-specific (sh-MKK7) shRNAs. Values express the percentage of live eGFP<sup>+</sup> cells relative to the number of live eGFP<sup>+</sup> cells in the same culture on day 0. Values denote mean&#x000a0;&#x000b1; SD (n&#x000a0;= 3).</p><p>(C) Western blots showing total and phosphorylated (P) proteins in U266 MM cells from (B). T/I, TPA/ionomycin.</p><p>(D) Trypan blue exclusion showing the survival of representative MM cell lines coexpressing sh-GADD45&#x003b2; or sh-ns and JNK1-specific (sh-JNK1) or sh-ns shRNAs on day 8 after lentivirus infection. Values denote mean&#x000a0;&#x000b1; SD (n&#x000a0;= 3).</p><p>(E) PI staining showing apoptotic cells (i.e., cells with sub-G<sub>1</sub> DNA content) in representative MM cell lines from (D). The percentages of apoptotic cells are depicted.</p><p>See also <xref rid="app2" ref-type="sec">Figure&#x000a0;S2</xref>.</p></caption><graphic xlink:href="gr2"/></fig><fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>The Potent Activity and Stability of D-Peptide Inhibitors of GADD45&#x003b2;/MKK7 In&#x000a0;Vitro</p><p>(A and B) ELISA GADD45&#x003b2;/MKK7 competition assays showing the IC<sub>50</sub> values of the active L-tetrapeptides (Ac-LTP1, Ac-LTP2) and D-tetrapeptides (Ac-DTP1, Ac-DTP2), before (A) and after (B) a 48&#x000a0;hr preincubation with human serum. Values express the percentage of inhibition of GADD45&#x003b2; binding to MKK7 relative to the binding in the absence of peptide and denote means&#x000a0;&#x000b1; SD (n&#x000a0;= 3). Ac-LNC, acetylated (Ac) negative control L-tetrapeptide (LNC); Ac-DNC, Ac negative control D-tetrapeptide (DNC).</p><p>(C) Coimmunoprecipitations (IP) performed with cell lysates prepared from human embryonic kidney 293T cells expressing ectopic HA-tagged GADD45&#x003b2; (HA-hGADD45&#x003b2;) and FLAG-tagged MKK7 (FLAG-hMKK7) and incubated with anti-FLAG antibody in the presence or absence of bioactive (Ac-DTP1 and Ac-DTP2) or inactive (Ac-DNC, Ac-DNC2, Ac-DNC3 and Ac-DNC4) D-tetrapeptides, as indicated. Western blots were developed using anti-HA or anti-MKK7 antibodies. -, incubation without D-tetrapeptides.</p><p>(D) Kinase assays (K.A.) showing MKK7 activity before (-) and after incubation with Ac-DTP1, Ac-DTP2 or control D-tetrapeptides as in (C), in the presence (+) or absence of recombinant human (h)GADD45&#x003b2;. T/I, TPA/ionomycin; UT, untreated.</p><p>See also <xref rid="app2" ref-type="sec">Figure&#x000a0;S3</xref> and <xref rid="app2" ref-type="sec">Tables S1</xref> and <xref rid="app2" ref-type="sec">S2</xref>.</p></caption><graphic xlink:href="gr3"/></fig><fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>The Potent and Cancer-Selective Activity of D-Peptide Inhibitors of GADD45&#x003b2;/MKK7 in MM Cells</p><p>(A) IC<sub>50</sub> values of z-DTP1 and z-DTP2 at 144&#x000a0;hr, as determined by [<sup>3</sup>H]thymidine incorporation, in MM cell lines that depend or do not depend on GADD45&#x003b2; for survival.</p><p>(B) [<sup>3</sup>H]Thymidine incorporation showing the survival of representative sensitive (U266) and resistant (RPMI-8226) MM cell lines from (A) after a 6-day treatment with the indicated concentrations of z-DTP1, z-DTP2, or Z-protected (z)-DNC.</p><p>(C) PI staining showing apoptotic cells in representative MM cell lines from (B), after treatment with 10&#x000a0;&#x003bc;M of z-DTP1, z-DTP2 or z-DNC for 6&#x000a0;days. The percentages of apoptotic cells are indicated.</p><p>(D) Trypan blue exclusion showing the survival of CD138<sup>+</sup> cells from MM patients (n&#x000a0;= 8) and healthy human PBMCs after treatment with z-DTP1 or z-DTP2 for 48 and 144&#x000a0;hr, respectively.</p><p>(B and D) Values express the percentage of live cells present in the treated cultures relative to the live cells present in the respective untreated cultures, represented as 100%, and denote means&#x000a0;&#x000b1; SD (B), or SEM (D) [PBMCs] (n = 3), (D) [MM] (n = 8).</p><p>See also <xref rid="app2" ref-type="sec">Figure&#x000a0;S4</xref> and <xref rid="app2" ref-type="sec">Table S3</xref>.</p></caption><graphic xlink:href="gr4"/></fig><fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>The High Target Specificity of DTP3 in Cells</p><p>(A) The structure of DTP3.</p><p>(B) Tryptophan fluorescence quenching analysis showing the dose-response curve of the -&#x00394;fluorescence values of GST-hMKK7 at 333&#x000a0;nm plotted against the concentration values of DTP3. The stoichiometry and K<sub>D</sub> value of the DTP3/MKK7 interaction on the basis of these data were 1:1 and 64.81&#x000a0;&#x000b1; 6.22&#x000a0;nM, respectively. Values denote means&#x000a0;&#x000b1; SD (n&#x000a0;= 3).</p><p>(C) Correlation plot of the relative <italic>GADD45B</italic> mRNA levels (qRT-PCR) and the DTP3 IC<sub>50</sub> at 144&#x000a0;hr ([<sup>3</sup>H]thymidine incorporation) in cancer cell lines of different tissues of origin. Values on the x axis express the logarithm to base 10 (log<sub>10</sub>) of the IC<sub>50</sub>. r<sub>S</sub>, Spearman correlation coefficient.</p><p>(D) K.A. showing JNK activity in representative sensitive (KMS-12, U266) and resistant (RPMI-8226) MM cell lines after treatment with DTP3 (10&#x000a0;&#x003bc;M). TNF&#x003b1; is shown as a positive control.</p><p>(E) Peptide pull-down showing the physical association of DTP3 with endogenous MKK7 in U266 and KMS-12 MM cells. SCRB D-peptide is used as a negative control. -, pull-down without D-tripeptide.</p><p>(F) [<sup>3</sup>H]Thymidine incorporation showing the survival of U266 and KMS-12 MM cells expressing sh-ns or sh-MKK7 shRNAs after a 6-day treatment with the indicated concentrations of DTP3. The IC<sub>50</sub> values of DTP3 are depicted. Values express the percentage of the counts per minute (cpm) measured with the treated cultures relative to the cpm measured with the respective untreated cultures and denote mean&#x000a0;&#x000b1; SD (n&#x000a0;= 3).</p><p>See also <xref rid="app2" ref-type="sec">Figure&#x000a0;S5</xref> and <xref rid="app2" ref-type="sec">Tables S4</xref> and <xref rid="app2" ref-type="sec">S5</xref>.</p></caption><graphic xlink:href="gr5"/></fig><fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>The Potent Activity of DTP3 in Primary MM Cells and Its Far Superior Cancer Cell Selectivity Compared with IKK&#x003b2; and Proteasome Inhibitors</p><p>(A) IC<sub>50</sub> values of DTP3 and bortezomib at 48&#x000a0;hr in CD138<sup>+</sup> cells from MM patients (n&#x000a0;= 8), CD138<sup>+</sup> cells from WM patients (n&#x000a0;= 2), human PBMCs, human BMSCs, human mesenchymal stem cells (MSCs), and mouse splenocytes and lymph node (LN) cells (top), as determined by trypan blue exclusion. In&#x000a0;vitro therapeutic indices (IC<sub>50</sub> in BMSCs/IC<sub>50</sub> in MM PCs) are depicted (bottom). MM and WM PC values denote means&#x000a0;&#x000b1; SEM. Other values denote means (n&#x000a0;= 3).</p><p>(B) Trypan blue exclusion showing the survival of CD138<sup>+</sup> cells from representative patients from (A), after treatment with DTP3 or bortezomib for 48&#x000a0;hr.</p><p>(C) Trypan blue exclusion showing the survival of CD138<sup>+</sup> cells from MM or WM patients after treatment with DTP3 (300&#x000a0;nM) or PS-1145 (20&#x000a0;&#x003bc;M) for 48&#x000a0;hr, in the presence of BMSCs.</p><p>(D) Trypan blue exclusion showing the survival of primary human BMSCs, human MSCs, and mouse LN cells and splenocytes after treatment with DTP3 (100&#x000a0;&#x003bc;M) or PS-1145 (20&#x000a0;&#x003bc;M) for 144&#x000a0;hr.</p><p>(B&#x02013;D) Values express the percentage of live cells present in the treated cultures relative to the live cells present in the respective untreated cultures and denote means&#x000a0;&#x000b1; SD (B), (C) [WM], (D) (n&#x000a0;= 3) or SEM (C) [MM] (n&#x000a0;= 9).</p><p>See also <xref rid="app2" ref-type="sec">Figure&#x000a0;S6</xref>.</p></caption><graphic xlink:href="gr6"/></fig><fig id="fig7"><label>Figure&#x000a0;7</label><caption><p>DTP3 Exhibits Potent Therapeutic Activity against MM, In&#x000a0;Vivo, in the Absence of Any Apparent Side Effects</p><p>(A) Pharmacokinetic (PK) values of DTP3 after single intravenous injection at the dose of 10&#x000a0;mg/kg. AUC, area under the plasma concentration versus time curve; CL, plasma clearance; t<sub>1/2</sub>, terminal half-life; V<sub>d</sub>, volume of distribution. Values denote means&#x000a0;&#x000b1; SD (n&#x000a0;= 3).</p><p>(B) Volumes of subcutaneous U266 myeloma xenografts in mice treated by continual infusion with DTP3 at a dose of 14.5&#x000a0;mg/kg/day or PBS for the times shown. Values denote means&#x000a0;&#x000b1; SEM (n&#x000a0;= 16). <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001.</p><p>(C) Images of representative myeloma-bearing mice (top) and isolated tumors (bottom) from (B) at day 28.</p><p>(D) Images of TUNEL assays showing apoptotic cells in representative tumors from (B). Scale bars represent 10&#x000a0;&#x003bc;M. Green, TUNEL; blue, DAPI.</p><p>(E) Western blots showing total and phosphorylated (P) JNK, and the unprocessed (filled arrowheads) and cleaved (open arrowheads) forms of caspase-3 and its proteolytic substrate, PARP-1, in representative tumors from (B).</p><p>(F) Percentage survival of mice bearing medullary KMS-12 MM xenografts and treated intermittently by infusion with DTP3 at a dose of 29.0&#x000a0;mg/kg/day or PBS (left; n&#x000a0;= 8, each group) for 8&#x000a0;weeks. Also shown is the median OS of each animal cohort (right). <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.0001.</p><p>See also <xref rid="app2" ref-type="sec">Figure&#x000a0;S7</xref> and <xref rid="app2" ref-type="sec">Table S6</xref>.</p></caption><graphic xlink:href="gr7"/></fig><fig id="fig8"><label>Figure&#x000a0;8</label><caption><p>Schematic Representation of the Therapeutic GADD45&#x003b2;/MKK7-Targeting Strategy in Cancer</p><p>Depicted is the crosstalk between the NF-&#x003ba;B and JNK pathways promoting the survival of cancer cells and cells exposed to inflammatory stimuli. Also illustrated is the NF-&#x003ba;B-dependent, Gadd45&#x003b2;/MKK7-mediated mechanism suppressing apoptotic JNK signaling in MM cells. Our therapeutic strategy to block the NF-&#x003ba;B survival function in a cancer-selective manner with DTP3 (green) is compared with conventional therapeutic approaches (e.g., IKK&#x003b2; and proteasome inhibitors; red) also aimed at inhibiting the NF-&#x003ba;B pathway in cancer. MAP3Ks, mitogen-activated protein kinase kinase kinases; ROS, reactive oxygen species.</p></caption><graphic xlink:href="gr8"/></fig></floats-group></article>